TY - JOUR
T1 - Molecular targets of quercetin with anti-inflammatory properties in atopic dermatitis
AU - Karuppagounder, Vengadeshprabhu
AU - Arumugam, Somasundaram
AU - Thandavarayan, Rajarajan A.
AU - Sreedhar, Remya
AU - Giridharan, Vijayasree V.
AU - Watanabe, Kenichi
PY - 2016/4
Y1 - 2016/4
N2 - Atopic dermatitis (AD) is an inflammatory skin disease. Over the past few decades, AD has become more prevalent worldwide. Quercetin, a naturally occurring polyphenol, shows antioxidant, anti-inflammatory, and antiallergic activities. Several recent clinical and preclinical findings suggest quercetin as a promising natural treatment for inflammatory skin diseases. Significant progress in elucidating the molecular mechanisms underlying the anti-AD properties of quercetin has been achieved in the recent years. Here, we discuss the use of quercetin as treatment for AD, with a particular focus on the molecular basis of its effect. We also briefly discuss the approaches to improve the bioavailability of quercetin.
AB - Atopic dermatitis (AD) is an inflammatory skin disease. Over the past few decades, AD has become more prevalent worldwide. Quercetin, a naturally occurring polyphenol, shows antioxidant, anti-inflammatory, and antiallergic activities. Several recent clinical and preclinical findings suggest quercetin as a promising natural treatment for inflammatory skin diseases. Significant progress in elucidating the molecular mechanisms underlying the anti-AD properties of quercetin has been achieved in the recent years. Here, we discuss the use of quercetin as treatment for AD, with a particular focus on the molecular basis of its effect. We also briefly discuss the approaches to improve the bioavailability of quercetin.
UR - http://www.scopus.com/inward/record.url?scp=84959486930&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84959486930&partnerID=8YFLogxK
U2 - 10.1016/j.drudis.2016.02.011
DO - 10.1016/j.drudis.2016.02.011
M3 - Review article
C2 - 26905599
AN - SCOPUS:84959486930
SN - 1359-6446
VL - 21
SP - 632
EP - 639
JO - Drug Discovery Today
JF - Drug Discovery Today
IS - 4
ER -